Thymoquinone Ameliorates Doxorubicin-Induced Cardiotoxicity in Swiss Albino Mice by Modulating Oxidative Damage and Cellular Inflammation

Mohammad Firoz Alam, Gyas Khan, Mohammed M. Safhi, Saeed Alshahrani, Rahimullah Siddiqui, Sivakumar Sivagurunathan Moni, and Tarique Anwer

1Neuroscience and Toxicology Unit, Department of Pharmacology and Toxicology, Faculty of Pharmacy, Jazan University, Jazan, Saudi Arabia
2Division of Pharmaceutical Biotechnology, Department of Pharmaceutics, College of Pharmacy, Jazan University, Jazan, Saudi Arabia

Correspondence should be addressed to Mohammad Firoz Alam; firozalam309@gmail.com

Received 31 October 2017; Revised 30 January 2018; Accepted 4 February 2018; Published 1 April 2018

1. Introduction

Doxorubicin is an anthracycline anticancer drug with highly effective chemotherapeutic agent which is used to treat various cancers, including haematological malignancies and others sarcomas [1, 2]. Although having good therapeutic potential, its uses are limited due to cumulative cardiotoxicity [3]. The mechanism of doxorubicin on tumor cells is completely different from the mechanism of its cardiotoxicity. The broad mechanism of antimalignancy effect on tumor cells includes the generation of reactive oxygen species and DNA damage by inhibition of topoisomerase II [4, 5], while the principal mechanism of doxorubicin is increased oxidative stress by increasing the level of ROS and lipid peroxidation [6, 7] and decreasing the level of antioxidant and sulphydryl groups [8–10]. Thus, doxorubicin cardiotoxicity once developed carry a poor prognosis and may be frequently fatal. To overcome this problem, several researches have been conducted to prevent the doxorubicin cardiotoxicity by using medicinal plants. Thus, it is clear that plant and plant products can be a useful
treatment to prevent the cardiotoxicity which is being used since ancient times. Therefore, a plant named *Nigella sativa*, which has great importance in medical history from ancient times to treat various diseases, is selected for further cardiotoxicity prevention in mice.

Thymoquinone is the active principle which is derived from the plant *Nigella sativa* and used as a wide spectrum of pharmacological action (Figure 1). Traditionally, *N. sativa* is used to treat many diseases including asthma, cough, hypertension, diabetes, inflammation, fever, headache, and many more [11, 12]. The main active ingredient of *N. sativa* is the thymoquinone which is also very popular with many pharmacological actions such as antioxidant, anti-inflammatory, hepatoprotective, and anticancer. Therefore, this plant is also called healers in ancient civilization to recent time research. Therefore, we have selected thymoquinone to investigate its protective effect against DOX-induced cardiotoxicity in mice.

2. Materials and Methods

2.1. Drugs and Chemicals. Thymoquinone and doxorubicin were supplied by Sigma-Aldrich, Co., Germany, through Byoni Trading Company of Saudi Arabia. LDH, CK-MB, AST, ALT, and other assay kits such as Interleukin IL2-ab221834 were used and managed from Abcam through Abdullah and Son Trading Company of Saudi Arabia, Dammam, KSA.

2.2. Experimental Animals. This experiment was performed on the Swiss albino mice (25–35 g) which were kept in the well-ventilated animal house of College of Pharmacy, Jazan University, KSA, for one week prior to starting the experimental protocol for proper acclimatization. The mice were provided with ideal laboratory conditions, given free access to diet and water during the whole experimental period.

2.3. Experimental Procedure. Five groups (Groups A, B, C, D, and E) of mice were prepared having each group of six mice. Group A was the control group given normal saline daily for 14 days; Group B was the toxic control, and it received DOX (15 mg/kg, b/w, i.p.) [13] once on the 13th day; Group C and D animals were given thymoquinone (10 and 20 mg/kg body weight, p.o.) [14], respectively, daily for 14 days and single dose of DOX (15 mg/kg, i.p.) on the 1st day of treatment. Group E was the thymoquinone control group, and it received thymoquinone (20 mg/kg body weight) daily up to 14 days. These protocols were approved by Jazan University Institutional Animal Care and Use Committee (IACUC).

2.4. Tissue Homogenization. On the 15th day mice were killed, blood samples were collected, and serum was isolated for the biochemical determinations. Immediately, hearts excised out, cleaned with ice-cold normal saline, and homogenized at 4°C. A 10% homogenate of the heart was prepared in 10 mM Tris-HCl (pH 7.4). The homogenate was centrifuged at 3000 rpm for 5 min at 4°C to remove the debris, and the supernatant was again centrifuged at 10,500 g for 30 min at 4°C to separate the postmitochondria supernatant (PMS). The homogenates were used for the assays of lipid peroxidation and PMS for glutathione, glutathione peroxidase, glutathione reductase, catalase, glutathione S-transferase, and superoxide dismutase [15].

2.5. Biochemical and Oxidative Stress Examination. Serum was used for estimation of aspartate aminotransferase (AST) by the Reitman and Frankel method [16], creatine kinase-MB (CK-MB) by Tsung et al.’s method [17], and the LDH estimation was carried out by the Lum and Gambino method [18].

The oxidative stress parameters were estimated by different procedures such as lipid peroxidation (LPO) by the method of Udley et al. [19], while antioxidants such as GSH by Jollow et al.’s method [20], catalase (CAT) by Claiborne’s method [21], glutathione peroxidase (GPx) by Mohandas et al.’s method [22], glutathione reductase (GR) by Carlberg and Mannervik’s method [23], SOD by Stevens et al.’s method [24], and glutathione S-transferase (GST) by Habig and Jakoby’s method [25]. The concentration of protein was measured by Lowry’s method [26].

2.6. Inflammatory Cytokine (IL2) Assay. Inflammatory cytokine (IL2) was estimated by Sandwich ELISA procedure given in the protocol for the tissue sample. The intensity of color formation was measured at 450 nm by using BioTek EL X 800 ELISA reader. The sample concentration was calculated by extra plotting on the standard curve.

2.7. Statistical Examination. Data were statistically analyzed with ANOVA (one-way) with Tukey–Karmer post hoc analysis, and data were represented as mean ± SD in a tabular form. The value $p < 0.05$ was considered as significant among the group.

3. Results

3.1. Effects of Thymoquinone on Serum Levels. The therapeutic effects of thymoquinone in blood serum markers of cardiac toxicity such as AST, ALT, LDH, and CK-MB levels are summarized in Table 1. The markers of cardiac toxicity enzymes were significantly higher in Group B as compared to Group A, while the thymoquinone-treated Groups C and D indicated a significant decrease in the level of these enzymes as compared to doxorubicin-treated Group B. There was no change found in Group E.
3.2. Effect of Thymoquinone on MDA Levels in Cardiac Tissue. Figure 2 illustrates the lipid peroxidation in different groups. In Group B, MDA level was increased \((p < 0.001)\) significantly in comparison to Group A. Treatment with thymoquinone in Groups C and D decreased MDA level significantly \((p < 0.01)\) and \((p < 0.001)\) in comparison to Group B.

3.3. Effect of Thymoquinone on Glutathione (GSH) Level in Cardiac Tissue. Figure 3 indicates the activity of glutathione in various groups. DOX treatment in Group B resulted in decreased level of glutathione significantly \((p < 0.01)\) as compared to Group A, while the treatment with thymoquinone in Groups C and D increased the level of glutathione significantly \((p < 0.01\) and \(p < 0.001)\) in comparison to Group B.

3.4. Effect of Thymoquinone on Antioxidant Enzyme in Cardiac Tissue. The effect of thymoquinone on antioxidant enzyme is summarized in Table 2. The important antioxidant enzyme contents were (CAT, SOD, GPx, GR, and GST) significantly decreased in Group B as compared to Group A. The treatment with thymoquinone enhanced the level of antioxidant enzymes in Groups C and D as compared to Group B. There were no side effects of thymoquinone on antioxidant enzyme in Group E.

3.5. Effect of Thymoquinone on Inflammatory Cytokine (IL2) in Cardiac Tissue. Doxorubicin administration in the mice Group B resulted in a significant increase in IL2 as compared to Group A. When it was treated with thymoquinone 10 and 20 mg/kg b/w, results indicated that elevated inflammatory cytokines were restored, and the concentration of cytokines was decreased in Groups C and D as compared to Group B (Figure 4).

4. Discussion

Doxorubicin is an anticancer agent having broad spectrum to treat the leukemias, Hodgkin’s lymphoma, and the other cancers such as bladder, breast, stomach, lungs, ovaries, thyroid, and soft tissue sarcoma [27, 28]. In spite of that its clinical uses are very limited because of its severity in cardiotoxicity manifested biochemically by elevation of serum enzyme marker of cardiotoxicity. The diagnostic serum marker enzymes of cardiotoxicity are AST, ALT, CK-MB, and LDH which leak from cardiac tissue damage to blood stream due to their tissue specificity and serum catalytic activity [29].

Our study also reveals the increase in levels of these enzymes in DOX-alone treated mice were significantly high. Administration of DOX may lead to the damage of the myocardial cell membrane, or it becomes permeable,
Table 2: The effect of thymoquinone on antioxidant enzymes in doxorubicin-mediated cardiotoxicity in the mice.

| Groups and treatments | CAT (nmole of H2O2 consumed/min/mg/protein) | SOD (nmol epinephrine protected from oxidation/min/mg protein) | GPx (nmol NADPH oxidized/min/mg protein) | GR (nmol NADPH oxidized/min/mg protein) | GST (nmol CDNB conjugate/min/mg protein) |
|-----------------------|--------------------------------------------|-------------------------------------------------------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|
| Group A (control)     | 35.93 ± 2.4                                | 12.51 ± 1.56                                                | 160.05 ± 3.10                           | 415.89 ± 1.34                           | 159.79 ± 4.56                           |
| Group B (DOX)         | 15.34 ± 2.60*                              | 5.29 ± 1.78***                                              | 83.94 ± 3.72**                          | 217.38 ± 2.34**                          | 80.26 ± 4.21**                           |
| Group C (DOX + Q10)   | 38.23 ± 2.30*                              | 8.45 ± 1.58**                                               | 115.34 ± 2.14*                          | 384.13 ± 2.13*                          | 120.46 ± 3.54*                           |
| Group D (DOX + TQ-20) | 34.45 ± 2.11**                             | 10.34 ± 1.36***                                             | 143.67 ± 2.13*                          | 420.22 ± 1.65**                          | 159.87 ± 2.45**                          |
| Group E TQ-20         | 30.23 ± 1.23**                             | 13.56 ± 2.10***                                             | 167.45 ± 1.46*                          | 428.00 ± 1.34*                          | 156.08 ± 2.33**                          |

Each value is the mean of six replicates with standard deviation; *p < 0.05, **p < 0.01, and ***p < 0.001 were significant when compared to normal control (Group A) and toxic control (Group-B) by performing Tukey-Kramer test.

resulting in the leakage of AST, ALT, CK-MB, and LDH in the blood. Treatment with thymoquinone in Groups C and D restored the activities by reducing these marker enzymes level toward normal in the serum. This may be due to potential protection and high antioxidant phenomena contributed by thymoquinone to the myocardium, thus reducing the damaging effects of doxorubicin to the cardiac muscle fibers, subsequently minimizing the leakage of such enzymes in the serum. ROS produced by doxorubicin treatment seems to be the leading cause of oxidative stress that causes cardiomyopathy [30, 31]. Oxidative stress can be confirmed by increased lipid peroxidation (LPO) and altered enzymatic and nonenzymatic antioxidant systems [32]. In our study, LPO level was increased significantly in Group B (DOX-alone treated group) animals. Thymoquinone has tendency to neutralize ROS like superoxide radicals, singlet oxygen, nitric oxide, and peroxynitrite, thereby reducing the damage to lipid membranes [33].

At the molecular levels, glutathione system plays an important role in cellular defense against oxidant [34] by scavenging reactive oxygen species (ROS) that showed it preventing nature. GSH depletion may cause an impaired cell defense that may lead to tissue injury. DOX treatment also resulted in decreased level of GSH in the heart. Our study showed that MDA level was decreased, and the level of GSH was increased in thymoquinone-treated Groups C and D. This indicates that treatment of thymoquinone scavenges free radicals which were produced by DOX treatment [19, 35]. In present study, the levels of enzymes like catalase (CAT) were significantly decreased in DOX-alone treated animals. This result indicates that DOX treatment cause formation of free radicals in heart and decreases its ability to detoxify reactive oxygen species. Thymoquinone however significantly increased the level of this antioxidant enzyme in DOX-treated groups. The protection thus offered may be due to their antioxidant and ROS scavenging nature. Administration of doxorubicin in Group B resulted in decrease in the level of superoxide dismutase (SOD) while in Groups C and D were further restored with treatment of thymoquinone. Superoxide dismutase (SOD) is a metalloenzyme that catalyses the dismutation of superoxide radicals and converts into H2O2 [36, 37].

GPx, GR, and GST are also important antioxidant enzymes which plays a predominant role in removing excess free radicals and hydroperoxides from the cell. GR utilizes the NADPH and maintains the GSH in a reduced form via converting GSH to GSSG by GPx, which is reconverted to GSH by GR, thus maintaining the pool of GSH. The decreased activity of GPx and GR may be due to the decreased content of GSH in the heart which was supported by Moron et al. [38]. The activity of GPx, GR, and GST was protected significantly by thymoquinone in the cardiotoxicity, and it was also supported by Nagi and Mansour [39].

The present study also concentrated on the investigation of molecular marker for inflammatory cytokine (IL2) in heart tissue. The result revealed that the administration of doxorubicin triggered the elevation of the cytokine level inside the heart tissue of the mice in Group B, and it was restored by the treatment of thymoquinone in Groups C and D. Thus, the oxidative stress and inflammatory cytokine are interlinked to each other which is
well documented by Federico et al. [40]. However, the molecular mechanism of thymoquinone is yet to be established. It needs more study to confirm the molecular mechanism.

**Conflicts of Interest**

The authors declare that they have no conflicts of interest.

**Acknowledgments**

The authors are thankful to the Dean, College of Pharmacy, Jazan University, to encourage and provide the facility.

**References**

[1] R. B. Weiss, "The anthracyclines, will we ever find a better doxorubicin," *Seminars in Oncology*, vol. 19, no. 6, pp. 670–686, 1992.

[2] E. H. Choi, H. J. Chang, J. Y. Cho, and H. S. Chun, "Cyto-protective effect of anthocyanins against doxorubicin-induced toxicity in H9c2 cardiomyocytes in relation to their antioxidant activities," *Food and Chemical Toxicology*, vol. 45, no. 10, pp. 1873–1881, 2007.

[3] B. H. Ali and G. Blunden, "Pharmacological and toxicological properties of *Nigella sativa*.," *Phytotherapy Research*, vol. 17, no. 4, pp. 299–305, 2003.

[4] D. A. Gewirtz, "A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotic Adriamycin and daunorubicin," *Biochemical Pharmacology*, vol. 57, no. 7, pp. 727–741, 1999.

[5] G. Minotti, P. Menna, E. Salvatorelli, G. Cairo, and L. Gianni, "Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity," *Pharmacological Reviews*, vol. 56, no. 2, pp. 185–229, 2004.

[6] B. Kalyanaraman, E. Perez-Reyes, and R. P. Mason, "Spin-trapping and direct electron spin resonance investigations of the redox metabolism of quinone anticancer drugs," *Biochimica et Biophysica Acta*, vol. 630, no. 1, pp. 119–130, 1980.

[7] J. H. Doroshow, "Effect of anthracycline antibiotics on oxygen radical formation in rat heart," *Cancer Research*, vol. 43, no. 2, pp. 460–472, 1983.

[8] P. K. Singal, R. J. Segstro, R. P. Singh, and M. J. Kutryk, "Changes in lysosomal morphology and enzyme activities during the development of Adriamycin-induced cardiomyopathy," *Canadian Journal of Cardiology*, vol. 1, no. 2, pp. 139–147, 1985.

[9] W. H. Talib and M. M. Abukhader, "Combinatorial effects of thymoquinone on the anti-cancer activity and hepatotoxicity of the prodrug CB 1954.," *Scienza Pharmacuetica*, vol. 81, no. 2, pp. 519–530, 2013.

[10] J. H. Doroshow, G. Y. Locker, J. Baldinger, and C. E. Myers, "The effect of doxorubicin on hepatic and cardiac glutathione," *Research Communications in Chemical Pathology and Pharmacology*, vol. 26, no. 2, pp. 285–295, 1979.

[11] E. Entok, M. C. Ustuner, C. Ozbaray et al., "Anti-inflammatory and anti-oxidative effects of *Nigella sativa* L.: FDG-PET imaging of inflammation," *Molecular Biology Reports*, vol. 41, no. 5, pp. 2827–2834, 2014.

[12] O. A. Al-Shabanah, O. A. Badary, M. N. Nagi, N. Al-Garably, A. AlRikabi, and A. M. AlBeikairi, "Thymoquinone protects against doxorubicin-induced cardiotoxicity without compromising its antitumor activity," *Journal of Experimental & Clinical Cancer Research*, vol. 17, no. 2, pp. 193–198, 1998.

[13] G. Khan, S. E. Haque, T. Anwer, M. N. Ahsan, M. M. Saifi, and M. F. Alam, "Cardioprotective effect of green tea extract on doxorubicin-induced cardiotoxicity in rats," *Acta Poloniae Pharmaceutica-Drug Research*, vol. 71, no. 5, pp. 861–868, 2014.

[14] M. M. Saifi, "Neuromodulatory effects of thymoquinone in extenuating oxidative stress in chlorpromazine treated rats," *Acta Poloniae Pharmaceutica-Drug Research*, vol. 73, no. 2, pp. 529–535, 2016.

[15] M. M. Saifi, M. F. Alam, G. Khuwaja et al., "Repeated exposure of sodium tellurite on the rat liver and on the potential mechanisms of the metalloid-induced hepatoxicity," *Acta Poloniae Pharmaceutica*, vol. 73, no. 3, pp. 675–682, 2016.

[16] S. Reitman and A. S. Frankel, "A colorimetric method for the determination of serum glutamic oxaloacetic and glutamic pyruvic transaminases," *American Journal of Clinical Pathology*, vol. 28, no. 1, pp. 56–63, 1957.

[17] S. H. Tsung, "Creatine kinase activity and isoenzyme pattern in various normal tissues and neoplasms," *Clinical Chemistry*, vol. 29, no. 12, pp. 2040–2043, 1983.

[18] G. Lumm and S. R. Gambino, "A comparison of serum versus heparinized plasma for routine chemistry tests," *American Journal of Clinical Pathology*, vol. 61, pp. 108–113, 1974.

[19] H. C. Utley, F. Bernheim, and P. Hochstein, "Effect of sulfhydryl reagent on peroxidation in microsomes," *Archives of Biochemistry and Biophysics*, vol. 260, pp. 521–531, 1967.

[20] D. J. Jollow, J. R. Mitchell, N. Zampaglione, and J. R. Gillette, "Bromobenzene-induced liver necrosis: protective role of glutathione and evidence for 3,4 bromobenzene oxide as the hepatotoxic metabolite," *Pharmacology*, vol. II, no. 3, pp. 151–169, 1974.

[21] A. Claiiborne, "Catalase activity," in CRC Handbook of Methods for Oxygen Radical Research, R. A. Greenwald, Ed., pp. 283–284, CRC, Boca Raton, FL, USA, 1985.

[22] J. Mohandis, J. J. Marshall, G. G. Duggin, J. S. Horvath, and D. Tiller, "Differential distribution of glutathione and glutathione related enzymes in rabbit kidneys: possible implication in analgesic neuropathy," *Cancer Research*, vol. 44, pp. 5086–5091, 1984.

[23] I.Carlberg and B. Mannervik, "Glutathione reductase levels in rat brain," *Journal of Biological Chemistry*, vol. 250, pp. 5475–5480, 1975.

[24] M. Stevens, I. Obrosova, X. Cao, C. V. Huysen, and D. A. Green, "Effects of DL-alpa-lipoic acid on peripheral nerve conduction, blood flow, energy metabolism and oxidative, blood flow, energy metabolism and oxidative stress in experimental diabetic neuropathy," *Diabetes*, vol. 49, no. 6, pp. 1006–1015, 2000.

[25] W. H. Habig and W. B. Jakoby, "Assays for differentiation of glutathione-S-transferase," in *Methods in Enzymology*, vol. 77, pp. 398–405, 1981.

[26] O. H. Lowry, N. J. Rosenbrough, A. L. Farr, and R. J. Randall, "Protein measurement with the Folin phenol reagent," *Journal of Biological Chemistry*, vol. 193, pp. 265–275, 1951.

[27] A. Brayfield, *Doxorubicin Martindale: the Complete Drug Reference*, Pharmaceutical Press, London, UK, 2014.

[28] S. Rossi, *Australian Medicines Handbook*, The Australian Medicines Handbook Unit Trust, ISBN 978-0-9805790-9-3, Adelaide, Australia, 2013.

[29] S. S. El Shaer, T. A. Salalheldin, N. M. Saied, and S. M. Abdelazizm, "In vivo ameliorative effect of cerium oxide nanoparticles in isoproterenol-induced cardiac toxicity," *Experimental and Toxicologic Pathology*, vol. 69, no. 7, pp. 435–441, 2017.
[30] J. Zheng, L. H. C. Michelle, M. M. B. Sattar, Y. Huang, and J.-S. Bian, “Cardioprotective effects of epigallocatechin-3-gallate against doxorubicin-induced cardiomyocyte injury,” European Journal of Pharmacology, vol. 652, no. 1–3, pp. 82–88, 2011.

[31] E. K. C. Kong, Y. Huang, J. E. Sanderson, K. B. Chen, S. Yu, and C. M. Yu, “A novel anti-fibrotic agent, baicalein for the treatment of myocardial fibrosis in spontaneously hypertensive rats,” European Journal of Pharmacology, vol. 658, no. 2-3, pp. 175–181, 2011.

[32] J. H. Doroshow, A book “Platinum Coordination Complexes in Cancer Chemotherapy: Proceedings of the Cancer Research”, Vol. 43, Springer, Berlin, Germany, 1983.

[33] M. Padmanbhan, M. Stanley, and P. Prince, “Effects of pharmacological amounts of S-allylcysteine on lipids in normal and isoproterenol-induced myocardial infarction in rats,” Journal of the Science of Food and Agriculture, vol. 86, no. 5, pp. 772–777, 2006.

[34] J. Kundu, D. H. Kim, J. K. Kundu, and K. S. Chun, “Thymoquinone induces heme oxygenase-1 expression in HaCaT cells via Nrf2/ARE activation: Akt and AMPKalpha as upstream targets,” Food and Chemical Toxicology, vol. 65, pp. 18–26, 2014.

[35] M. Khader and P. M. Eckl, “Thymoquinone: an emerging natural drug with a wide range of medical applications,” Iranian Journal of Basic Medical Sciences, vol. 17, no. 12, pp. 950–957, 2014.

[36] B. A. Freeman and J. D. Crapo, “Biology of disease free radicals and tissue injury,” Laboratory Investigation, vol. 47, no. 5, pp. 412–426, 1982.

[37] G. Ramesh and W. Brian, “Inflammatory cytokines in acute renal failure,” Kidney International, vol. 66, no. 91, pp. S56–S61, 2004.

[38] M. S. Moron, J. W. Bepierre, and B. Mannerwick, “Levels of glutathione reductase and glutathione S-transferase in rat lung and liver,” Biochimica Et Biophysica Acta, vol. 582, no. 1, pp. 67–78, 1979.

[39] M. N. Nagi and M. A. Mansour, “Protective effect of thymoquinone against doxorubicin induced cardiotoxicity in rats: a possible mechanism of protection,” Pharmacological Research, vol. 41, no. 3, pp. 283–289, 2000.

[40] A. Federico, F. Morgillo, C. Tuccillo, F. Ciardiello, and C. Loguercio, “Chronic inflammation and oxidative stress in human carcinogenesis,” International Journal of Cancer, vol. 121, no. 11, pp. 2381–2386, 2007.